Role of dose-dense chemotherapy in high-risk early breast cancer

Eva Blondeaux, Francesca Poggio, Lucia Del Mastro

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of review Adjuvant chemotherapy for breast cancer significantly reduces the risk of recurrence and improves overall survival (OS). The purpose of the current article is to review available evidence on dose-dense chemotherapy, also focusing on special population, including premenopausal women and those with HER2-positive disease. Recent findings A recent patient-level meta-analysis showed that the use of dose-dense chemotherapy is associated with significant reduction in disease recurrence, breast cancer mortality and improvement in OS. The benefit of dose-dense chemotherapy is irrespective from HER2 status, although women with HER2-positive disease enrolled in trials included in the meta-analysis did not receive the current standard of treatment with anti-HER2 agents. Among premenopausal women, dose-dense chemotherapy improved OS, and thus should be considered standard of care for them. Summary In conclusion, high-risk early stage breast cancer patients should be treated with (neo)adjuvant dose-dense anthracycline-based chemotherapy followed by paclitaxel. In the era of trastuzumab, the benefit of dose-dense chemotherapy is still unclear for patients with HER2-positive breast cancer.

Original languageEnglish
JournalCurrent Opinion in Oncology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Breast Neoplasms
Drug Therapy
Survival
Meta-Analysis
Recurrence
Women's Rights
Anthracyclines
Adjuvant Chemotherapy
Standard of Care
Paclitaxel
Mortality
Population
Therapeutics

Keywords

  • breast cancer
  • dose-dense
  • HER2-positive
  • premenopausal

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Role of dose-dense chemotherapy in high-risk early breast cancer. / Blondeaux, Eva; Poggio, Francesca; Del Mastro, Lucia.

In: Current Opinion in Oncology, 01.01.2019.

Research output: Contribution to journalReview article

@article{8c00e22f20114ba08b5364da7c84a891,
title = "Role of dose-dense chemotherapy in high-risk early breast cancer",
abstract = "Purpose of review Adjuvant chemotherapy for breast cancer significantly reduces the risk of recurrence and improves overall survival (OS). The purpose of the current article is to review available evidence on dose-dense chemotherapy, also focusing on special population, including premenopausal women and those with HER2-positive disease. Recent findings A recent patient-level meta-analysis showed that the use of dose-dense chemotherapy is associated with significant reduction in disease recurrence, breast cancer mortality and improvement in OS. The benefit of dose-dense chemotherapy is irrespective from HER2 status, although women with HER2-positive disease enrolled in trials included in the meta-analysis did not receive the current standard of treatment with anti-HER2 agents. Among premenopausal women, dose-dense chemotherapy improved OS, and thus should be considered standard of care for them. Summary In conclusion, high-risk early stage breast cancer patients should be treated with (neo)adjuvant dose-dense anthracycline-based chemotherapy followed by paclitaxel. In the era of trastuzumab, the benefit of dose-dense chemotherapy is still unclear for patients with HER2-positive breast cancer.",
keywords = "breast cancer, dose-dense, HER2-positive, premenopausal",
author = "Eva Blondeaux and Francesca Poggio and {Del Mastro}, Lucia",
year = "2019",
month = "1",
day = "1",
doi = "10.1097/CCO.0000000000000571",
language = "English",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Role of dose-dense chemotherapy in high-risk early breast cancer

AU - Blondeaux, Eva

AU - Poggio, Francesca

AU - Del Mastro, Lucia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose of review Adjuvant chemotherapy for breast cancer significantly reduces the risk of recurrence and improves overall survival (OS). The purpose of the current article is to review available evidence on dose-dense chemotherapy, also focusing on special population, including premenopausal women and those with HER2-positive disease. Recent findings A recent patient-level meta-analysis showed that the use of dose-dense chemotherapy is associated with significant reduction in disease recurrence, breast cancer mortality and improvement in OS. The benefit of dose-dense chemotherapy is irrespective from HER2 status, although women with HER2-positive disease enrolled in trials included in the meta-analysis did not receive the current standard of treatment with anti-HER2 agents. Among premenopausal women, dose-dense chemotherapy improved OS, and thus should be considered standard of care for them. Summary In conclusion, high-risk early stage breast cancer patients should be treated with (neo)adjuvant dose-dense anthracycline-based chemotherapy followed by paclitaxel. In the era of trastuzumab, the benefit of dose-dense chemotherapy is still unclear for patients with HER2-positive breast cancer.

AB - Purpose of review Adjuvant chemotherapy for breast cancer significantly reduces the risk of recurrence and improves overall survival (OS). The purpose of the current article is to review available evidence on dose-dense chemotherapy, also focusing on special population, including premenopausal women and those with HER2-positive disease. Recent findings A recent patient-level meta-analysis showed that the use of dose-dense chemotherapy is associated with significant reduction in disease recurrence, breast cancer mortality and improvement in OS. The benefit of dose-dense chemotherapy is irrespective from HER2 status, although women with HER2-positive disease enrolled in trials included in the meta-analysis did not receive the current standard of treatment with anti-HER2 agents. Among premenopausal women, dose-dense chemotherapy improved OS, and thus should be considered standard of care for them. Summary In conclusion, high-risk early stage breast cancer patients should be treated with (neo)adjuvant dose-dense anthracycline-based chemotherapy followed by paclitaxel. In the era of trastuzumab, the benefit of dose-dense chemotherapy is still unclear for patients with HER2-positive breast cancer.

KW - breast cancer

KW - dose-dense

KW - HER2-positive

KW - premenopausal

UR - http://www.scopus.com/inward/record.url?scp=85071393525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071393525&partnerID=8YFLogxK

U2 - 10.1097/CCO.0000000000000571

DO - 10.1097/CCO.0000000000000571

M3 - Review article

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

ER -